gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · HRTXHealthcarePharmaceuticals

Heron Therapeutics, Inc. (HRTX)

$0.2986+4.88%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.30▼ 73.81% in range
Nov 4, 2025Low $0.27 · High $1.49Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Heron Therapeutics closed at $0.30 on Nov 4, up 4.88%, 80.0% below its 52-week closing high. Volume of 969.0K shares was 0.51× its 20-day average (below normal).

Split-adjusted performance: -10.0% over one month, -77.2% over six months, -74.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $37.67M, up 1.3% from a year earlier, with a net margin of -14.6%.

Short interest was 36.7M shares at the Oct 15 settlement, down 20.2% from the prior report (25.7% of float, 14.2 days to cover).

Market cap$56.7M189.9M shares
Revenue · quarter$37.7M+1.3% YoY
Diluted EPS$-0.03—
P/E · TTM—P/S 0.4×
Net margin-14.6%Gross 69.3%
Dividend yieldNone
52-week range0.27 – 1.49−80.0% from high
Volume969.0K0.51× 20-day avg
Volatility · 60d88.0%Annualised
Short % of float25.7%14.2 days to cover
Net cash-$100.0MCash $42.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.3%1M −10.0%3M −40.2%6M −77.2%YTD −77.0%1Y −74.7%3Y −52.6%5Y −97.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum8
Revenue growth42
Net margin61
Value (low P/E)—
Size33

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short36.7M−20.2% vs prior
Days to cover14.2Settled Oct 15
% of float25.7%
Short vol. 10d48.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HRTXHeron Therapeutics$0.2986+4.88%−77.2%+1.3%−14.6%—$56.7M
RNTXRein Therapeutics$0.6587−1.32%−43.7%———$56.8MCompare
XLOXilio Therapeutics$8.71+0.35%+10.3%+131.2%−34.1%—$57.3MCompare
RFLRafael Holdings$1.07−0.93%−14.4%−30.3%−3760.7%—$55.8MCompare
ONCYOncolytics Biotech$0.4248+8.92%−53.8%———$55.7MCompare
CTORCitius Oncology$0.5470−0.55%−39.8%—−597.4%—$57.9MCompare
BOLDBoundless Bio$2.40+0.84%+51.9%———$55.5MCompare
NMADNomad Power Solutions$3.60+2.27%————$58.0MCompare
CLNNClene$4.10+8.75%−42.7%+233.3%−14915.6%—$58.3MCompare

News about Heron Therapeutics

All news →
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026GlobeNewswire Inc. · Oct 27, 2026▲ Positive

Quick answers

What does Heron Therapeutics do?
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs.
What is HRTX's market cap?
$56.69M, based on the Nov 4 close of $0.30.
Does Heron Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HRTX is sold short?
36.7M shares, 25.7% of float, as of Oct 15, 2026.
What sector is HRTX in?
Healthcare, in the Pharmaceuticals industry.

About Heron Therapeutics

Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

HQ: San Diego, CA128 employeesListed Aug 27, 1987herontx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology